The only treatment approved specifically for epithelioid sarcoma TAZVERIK offered higher ORR responses as a first‑line vs as a later‑line therapy1,2

Tazemetostat (TAZVERIK®) is included in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Soft Tissue Sarcomas with a category 2A recommendation as the only preferred regimen for appropriate patients with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.3

View the efficacy of TAZVERIK

See how TAZVERIK demonstrated efficacy in epithelioid sarcoma patients.

View the safety of TAZVERIK

Learn more about how safety and tolerability were evaluated in the trial.

Questions about TAZVERIK?

Epizyme is here to help. Request to have a representative contact you.

ORR=overall response rate; EZH2=enhancer of zeste homologue

References: 1. TAZVERIK (tazemetostat) Prescribing Information. Cambridge, MA: Epizyme, Inc., July 2020. 2. Gounder M, Schöffski P, Jones RL, et al. Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study. Lancet Onc. 2020;21(11):1423-1432. doi: 10.1016/S1470-2045(20)30451-4. 3. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Soft Tissue Sarcoma V.2.2021. © National Comprehensive Cancer Network, Inc. 2021. All rights reserved. Accessed July 21, 2021. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.